Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study
Military Medical Research volume 8, Article number: 32 (2021)
Pre-exposure prophylaxis (PrEP) prevents human immunodeficiency virus (HIV) infection, but its use remains low among U.S. military men who have sex with men (MSM), likely due to mis-matching with personal preferences. We conducted a study to characterize preferences to PrEP measures within this population.
HIV-negative military MSM were recruited through a closed, Lesbian, Gay, Bisexual, and Transgendered (LGBT) military social media group. The survey was anonymous, and consisted of five experimentally varied attributes in service delivery: dosing method, provider type, visit location, lab work evaluation location, and dispensing venue. Relative importance and part-worth utility scores were generated using hierarchical bayes (HB) estimation, and the randomized first choice model was used to examine participation interest across eight possible PrEP program scenarios.
A total of 429 participants completed the survey. Among the eight scenarios with varying attributes, the most preferred scenario featured a daily tablet, PrEP injection or implant, along with a military provider, smartphone/telehealth visit, and on-base locations for lab evaluation and medication pick-up. The results also emphasized the importance for providers to be familiar with PrEP prescription knowledge, and to provide interactions sensitive to sexual identity and mental health.
A PrEP program consisting of daily tablet is preferred in military healthcare settings is preferred. Long-acting implants and injections are also desired.
Each year, there are approximately 350 new cases of human immunodeficiency virus (HIV) infections within members of the U.S. military; with those most affected being younger, Black, and men who have sex with men [1,2,3,4,5,6]. When taken as prescribed, pre-exposure prophylaxis (PrEP) effectively prevents HIV infection [7,8,9,10]. However, the percentage of at-risk military members taking PrEP measures is only 16%, and even lower in members of color .
Factors that contribute to the low PrEP engagement rate include access pathways, delivery mechanisms, and dosing methods impacted by geographic, psychological, and adherence barriers [11,12,13,14,15,16,17,18]. For military members, PrEP availability largely depends on geographic proximity to large medical facilities with specialty services, as evidenced by 41% of all military PrEP prescriptions originating from military medical centers in three locations in the U.S. Additionally, 60% of all military PrEP prescriptions also occur only after consultation with an infectious disease specialist . Features of PrEP delivery programs suitable for military MSM remain unknown.
Health services designed around preferences in terms of product type, delivery method, and location settings have been shown to produce improved outcomes and retention in care [19,20,21]. Stated preference methods, such as conjoint analysis, quantify preference data of new market entrants and product attributes [16, 17, 22,23,24,25,26]. In conjoint analysis, products/programs are viewed as a composition of various attributes that possess a certain amount of value (part-worth utility score) determined by preference. By quantifying these part-worth utility scores for preferred attributes, these scores can then be entered into market simulation models to predict how respondents might respond to any potential combination of attribute levels [16, 17, 22,23,24,25,26]. We used conjoint analysis to identify preferred attributes that are most influential to at-risk U.S. military MSM’s decision to take PrEP within the military healthcare system.
A convenience sample of self-reported HIV-negative, U.S. military MSM and trans-individuals were recruited between March and April 2020 through a closed Facebook group with over 7000 LGBT U.S. military members. The group administrators placed monthly advertisements describing the study on the group’s main forum. Those interested could click on a link to access an online study disclosure form with a ‘click to consent’ procedure. An option to provide an e-mail address that was not linked to survey responses was offered to participants who opted to receive $5 compensation for questionnaire completion. The study was approved by the Yale University Institutional Review Board.
To collect and quantify respondent preference data, an adaptive choice-based conjoint (ACBC) survey instrument was developed based on a starting set of PrEP program attributes resulting from review of the literature of previous PrEP preference conjoint experiments, and then refined through in-depth, qualitative interviews between PrEP experts and U.S. military MSM [2,3,4,5, 11, 12, 14, 15, 27,28,29,30,31,32,33,34,35,36,37,38,39]. The final survey instrument focuses on modifiable PrEP program characteristics, and consists of the following five attributes: dosing method [daily oral tablet, on-demand tablet regimen (two tablets before sex, one tablet for two days after), rectal douche (before sex), injection (every 2 months), implant (once a year)], provider type (military, civilian), visit location (on-base, off-base, smartphone app), dispensing venue (on-base, off-base, mail delivery), and lab evaluation (on-base, off-base, home-based mail kit). The survey was piloted by the author (JIG) using a convenience sample of eleven military MSM members within the targeted social media group for concept testing, and the descriptions and wording of three attribute categories and two attribute level choices were revised for clarification based on feedback. Additional figure shows a sample item of the conjoint survey, and Table 1 describes the program attributes in the survey. Additional information that we collected include age, race, ethnicity, rank type (officer, enlisted or warrant officer), military branch, geographic region, PrEP experience [“Have you ever used PrEP (Pre-Exposure Prophylaxis)?”], depressive symptoms with the Patient Health Questionnaire-2 (PHQ2) [40, 41], and the HIV Incidence Risk Index for MSM (HIRI-MSM), which identifies MSM at high risk . Measures to explore levels of satisfaction with a current level of HIV protection and disclosure discomfort within interactions with a primary care provider were also collected.
The final survey was loaded into Lighthouse Studio 9, and an experimental design module was used to pre-test the design with 500 simulated respondents for optimal choice task configuration. The final design produced a survey where each level within an attribute was seen at least three times per respondent; achieving a high degree of precision at the individual level with a standard of error of < 0.03 and all efficiencies reporting at 1.00 .
Respondent enrolment and exclusion are shown in CONSORT style in Fig. 1. To ensure data integrity and eliminate random or duplicate responders, security features within the Sawtooth software and servers recognize returning study participants through the use of internet browser cookies and IP addresses. It also prevents repeated or duplicate attempts to retake the survey . Since extensive pilot testing required at least 10 to 15 min, responses completed in less than 10 min (or if a respondent selected the same answer for all items) were excluded. Furthermore, the root likelihood (RLH) fit statistic for each respondent was analyzed to evaluate within-respondent choice consistency. RLH, which has a probability value from 0 to 1.0, was used to discriminate between respondents who answered choice-questions consistently or randomly . The survey design was tested by 1000 computer-generated mock respondents to determine the median RLH for "random responders" at the 95% percentile (0.5178 RLH). Survey respondents with an RLH below this score were excluded, as the inclusion of "random responders" can affect the calculation of preference scores and participation rates .
For conjoint analyses, a hierarchical bayes (HB) procedure was used to estimate part-worth utility scores (PWUS) on an individual level for accuracy and efficiency [46, 47], and was used to analyze the PWUS of the aggregated sample across all 16 attribute levels. The resulting PWUS of the levels under each attribute category are zero-centered; meaning that the sum of the level scores under each attribute category equal to zero. Scores that are further away from zero (0) indicate a stronger positive or negative preference for the level choice in relation to the other level choices under the same attribute [39, 43, 47]. After identifying each attribute level PWUS, the attribute relative importance scores (RIS) was calculated to characterize the magnitude of influence that each attribute category has on the respondent preference decision-making. The RIS for this study was calculated by dividing the range of PWUS for levels under each attribute by the sum of the ranges, and then multiplying by 100 [48, 49]. For example, an attribute RIS at 45% denotes that 45% of an individual’s decision making for program engagement is influenced by preferences within that attribute category. The PWUS were then used to predict the share of preference (participation interest) among eight hypothetical PrEP program scenarios. PrEP program scenarios were configured after a variety of currently available or hypothetical PrEP program models. For this study, participation rates for these PrEP scenarios were generated using the randomized first choice model, in which PWUS are summed across the levels corresponding to each option, and then exponentiated and rescaled, so they sum to 100 [48, 49]. This approach is based on the assumption that respondents or consumers will prefer a product with the highest composite utility (or value) adjusting for both attribute and program variability . The randomized choice model accounts for variation in each participant’s total utility for each option and error in point estimates of the utility, and has been shown to have better predictive ability than other shares of preference models . All data analyses were performed using XLSTAT and Sawtooth Lighthouse Studio 9.0.
A total of 429 respondents were included in the analyses. The participants were 30 years of age on average, mostly white (72.0%) and cis-gendered male (96.7%, Table 2). 46.4% were officers, and 48.7% were in the Army (48.7%). Sixty-two point seven percent of the participants had depressive symptoms, 89.3% had high objective risk for acquiring HIV . Eighty-three point nine percent of the participants reported at least one episode of condomless receptive anal sex (CRAS) within the prior six months. Thirty-six point eight percent of the participants were “somewhat” or “extremely” uncomfortable with talking about sex with their primary care providers (PCP).
When stratified by PrEP experience, those with no previous PrEP experience were mostly of non-Hispanic ethnicity, stationed in the Western region of the U.S., and more likely to report having only a high school education. These participants also reported a lower number of male and HIV-positive partners within the last six months, and tended to report being less satisfied with their current level of HIV protection.
Relative importance and part-worth utility scores
Table 3 shows the relative importance scores (RIS) of the five attributes and Table 4 shows the part-worth utility scores (zero-centered) for each attribute level. Overall, the dosing method was the most important attribute, regardless of PrEP experience. For participants reporting PrEP experience, the daily tablet was the most preferred dosing method option, followed by the on-demand tablet regimen. For those with no previous experience with PrEP, the bi-monthly PrEP injection was the most preferred dosing method option, with the yearly implant and daily tablet preferred but to a lesser degree. Among the remaining attributes, both groups generally preferred the option to see a military healthcare provider, to use a smartphone to conduct the PrEP visit, and to utilize an on-base location for laboratory evaluation and receipt of medication. Thus, respondents with no PrEP experience are less likely to select “None” compared to PrEP-experienced individuals, and are more likely to initiate PrEP regardless of program configuration.
Preferences for PrEP program scenarios
Table 5 describes the configuration of the eight PrEP programs and Table 6 displays the participation interest scores across each individual PrEP program scenario if it were available to them as an option.
The total participation interest rate for the aggregate sample was 66.4% for Scenario 1 (On-Base Military Daily Tablet; the currently-available PrEP program within the military healthcare system today). Incorporating a smartphone PrEP visit feature into a military daily tablet PrEP program (Scenario 2, Smartphone Military Daily Tablet), and this program scenario resulted in a 3% increase in total participation interest rate to 69.6%. Scenario 2 also resulted in significant gain in participation interest among those with no PrEP experience (to 78.0%). Offering an on-demand tablet regimen within a smartphone-based military PrEP program (Scenario 3, Smartphone Military On-Demand) resulted in a marginal increase in the overall participation interest rate (67.6%) and a reduction in respondents with no PrEP experience (67.4%).
Programs with longer-acting PrEP options in the form of injectables and implants (Scenarios 4 through 6) were configured for military members whose personal or work-related circumstances compel the individual to seek PrEP options with fewer dosing administrations or from a remote location with limited resources. When compared to the Scenario 1, an injectable PrEP option did not alter participation interest rate in PrEP-experienced individuals, but garnered a higher participation interest rate in those with no PrEP experience (80.5%) when injectable PrEP is offered within a smartphone-based military PrEP program (Scenario 4, Smartphone Military Injection), and a participation interest rate of 78.3% when offered through a distance-based military PrEP program (Scenario 5, Remote Military Injection). Similarly, a PrEP implant offered within a smartphone-based military PrEP program (Scenario 6, Smartphone Military Implant) did not change the participation interest rate in PrEP-experienced respondents (66.4%) but resulted in a higher participation rate in subjects without experience with PrEP (78.7%).
Off-base program configurations (Scenario 7 & 8) were configured to represent civilian-equivalent, off-base, PrEP programs that circumvent the military and on-base aspects of a PrEP program. These programs had the lowest overall participation interest rate (57.7% with daily tablet PrEP program, and 40.5% with rectal douche option).
The current study demonstrated an overall preference for daily tablet PrEP services at an on-base location vs. civilian and off-base settings, yet those with no previous PrEP experience have a stronger preference for longer-acting injectables and implants. Additionally, over half of all respondents screened positive for depressive symptoms, the majority of respondents engage in risk behaviors that categorize them as having a high risk for acquiring HIV. Over one-third of respondents reported discomfort in discussing their sex life with PCP. With a growing body of literature suggesting a link between depression and sexual risk behaviors among MSM [50,51,52], it may be beneficial for PrEP-prescribing providers to provide PrEP clinics that are sensitive and inclusive to sexual identity and to remain vigilant to address factors related to mental and sexual health specific to MSM.
In the conjoint experiment, dosing method attribute was the most critical and influential preference factor within a PrEP delivery program, with a strong overall preference for a daily tablet among the total sample. Among those with no previous PrEP experience, a dominant preference for PrEP injectables and implants suggests that a demand for these longer-acting PrEP methods exists within this population if these alternatives become available. The long-acting injectable cabotegravir for PrEP has demonstrated superiority over oral tablet PrEP [53, 54], and could become further prioritized by future users as efficacy data becomes more widely known. The MK-8591-eluting PrEP implants have also achieved promising preliminary results , with clear benefit over daily tablet for individuals with adherence concerns or an unpredictable work schedule . The expeditionary nature often entails military members to relocate, deploy, or miss regular follow-up appointments [57, 58]. Therefore, availability of longer-acting PrEP modalities should be an important component of the future PrEP programs for military members.
The current study confirmed a preference to see a military provider for PrEP services, highlighting the important role of military healthcare providers. However, a survey of military health care providers regarding PrEP knowledge and prescription habits revealed that 49% rated their knowledge as poor and only 29% had ever prescribed it . Additionally, most military members receive their PrEP prescription only after seeing an infectious disease specialist , suggesting that military PCP may feel uncomfortable prescribing PrEP. This lower level of PrEP knowledge and prescription practice may contribute to the heterogenous nature of PrEP availability that currently seems dependent on a military member’s geographic location , and could explain the statistically significant difference in respondents’ regions of station within this study when stratified by PrEP experience. An increase in PrEP knowledge has been associated with an increase in prescribing habits , again suggesting military PCP with necessary training and resources to comfortably prescribe PrEP may help military members engage in a wider availability of PrEP services without the extra step of a referral to an infectious disease specialist. Further research is needed to explore the preference for a military provider within this context, and how this preference can best be leveraged to improve PrEP implementation.
In the current study, respondents with no previous PrEP experience reported fewer male sexual partners and fewer HIV-positive partners within the last six months, and more likely to report being unsatisfied with their current level of HIV protection. Given that sexual contact with men and condomless sex have been found to be the most common indications for initiating PrEP among military MSM , further studies will need to explore what type of PrEP programs could best accommodate the desire for more intimacy with male partners without using condoms.
This study has limitations. First, this study utilized self-report from a convenience sample recruited from an online social media group comprised of U.S. military members who identify themselves as LGBT. As a result, we could not verify actual eligibility (e.g., inclusion and exclusion criteria). Having said that, existing literature that compared MSM recruitment via online methods versus in-person had found similar samples of HIV/STI prevalence and HIV-testing patterns among MSM [60, 61]. Also, our findings may not be generalizable to at-risk military members who have sex with men but do not identify themselves as being MSM or LGBT. We also excluded a large number of respondents based on RLH cut-offs. There is a rising trend of “random responders” and “survey-bots” that attempt duplicate submission of surveys that provide financial compensation and can impact preference data if included within final the analyses . These RLH standards follow evidence-based consistency cut-offs to eliminate these “random responders”, but could nonetheless introduce sample selection bias. Finally, reporting preferences is distinct from actual behavior. The final evidence will come only from future studies when the preference data are implemented into practice.
In military members with a high risk of acquiring HIV, PrEP programs with the following features are preferred: daily tablet, injection or implant, medical visit provided by a military healthcare provider through a telehealth smartphone app, and on-base locations to provide laboratory samples and to receive PrEP medication.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
adaptive choice-based conjoint
Army Post Office
consolidated standards of reporting trials
condomless receptive anal sex
HIV incidence risk index for men who have sex with men
human immunodeficiency virus
bi & transgender
men who have sex with men
Outside Continental United States
patient health questionnaire-2
primary care provider
part-worth utility scores
relative importance score
Armed Forces Health Surveillance B. Update: Routine screening for antibodies to human immunodeficiency virus, civilian applicants for U.S. military service and U.S. Armed forces, active and reserve components, January 2013-June 2018. MSMR. 2018;25(9):2–8.
Blaylock JM, Hakre S, Okulicz JF, Garges E, Wilson K, Lay J, et al. HIV preexposure prophylaxis in the U.S. military services - 2014-2016. MMWR Morb Mortal Wkly Rep. 2018;67(20):569–74. https://doi.org/10.15585/mmwr.mm6720a1.
Hakre S, Scoville SL, Pacha LA, Peel SA, Kim JH, Michael NL, et al. Brief report: sexual risk behaviors of HIV seroconverters in the US army, 2012-2014. J Acquir Immune Defic Syndr. 2015;70(4):456–61. https://doi.org/10.1097/QAI.0000000000000778.
Patterson SB, Rivera D, Sunil TS, Okulicz JF. Evaluation of extragenital screening for gonorrhea and chlamydia in HIV-infected active duty air force members. MSMR. 2014;21(11):7–9.
Hakre S, Mydlarz DG, Dawson P, Danaher PJ, Gould PL, Witkop CT, et al. Epidemiology of HIV among US air force military personnel, 1996-2011. PLoS One. 2015;10(5):e0126700. https://doi.org/10.1371/journal.pone.0126700.
Blaylock JM, Hakre S, Decker CF, Wilson B, Bianchi E, Michael N, et al. HIV PrEP in the military: Experience at a tertiary care military medical center. Mil Med. 2018;183(suppl_1):445–9.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. https://doi.org/10.1056/NEJMoa1110711.
Grant RM, Lama JR, Anderson PL, Mcmahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. https://doi.org/10.1056/NEJMoa1011205.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. https://doi.org/10.1016/S0140-6736(13)61127-7.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. https://doi.org/10.1056/NEJMoa1108524.
Lykins WR, Luecke E, Johengen D, Van Der Straten A, Desai TA. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Deliv Transl Res. 2017;7(6):805–16. https://doi.org/10.1007/s13346-017-0391-6.
Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–e10. https://doi.org/10.1016/S2352-3018(17)30089-9.
Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. 2020;7(2):e113–e20. https://doi.org/10.1016/S2352-3018(19)30341-8.
Pines HA, Gorbach PM, Weiss RE, Hess K, Murphy R, Saunders T, et al. Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav. 2013;17(3):1002–15. https://doi.org/10.1007/s10461-012-0358-z.
Hendrix CW. HIV antiretroviral pre-exposure prophylaxis: Development challenges and pipeline promise. Clin Pharmacol Ther. 2018;104(6):1082–97. https://doi.org/10.1002/cpt.1227.
Dubov A, Fraenkel L, Yorick R, Ogunbajo A, Altice FL. Strategies to implement pre-exposure prophylaxis with men who have sex with men in Ukraine. AIDS Behav. 2018;22(4):1100–12. https://doi.org/10.1007/s10461-017-1996-y.
Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31(5):545–53. https://doi.org/10.1080/09540121.2018.1557590:1-9.
Touger R, Wood BR. A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP). Curr HIV/AIDS Rep. 2019;16(1):113–9. https://doi.org/10.1007/s11904-019-00430-z.
Swift JK, Callahan JL. The impact of client treatment preferences on outcome: a meta-analysis. J Clin Psychol. 2009;65(4):368–81. https://doi.org/10.1002/jclp.20553.
Adamson SJ, Bland JM, Hay EM, Johnson RE, Jones GT, Kitchener H, et al. Patients' preferences within randomised trials: systematic review and patient level meta-analysis. BMJ. 2008;337:a1864.
Graff FS, Morgan TJ, Epstein EE, Mccrady BS, Cook SM, Jensen NK, et al. Engagement and retention in outpatient alcoholism treatment for women. Am J Addict. 2009;18(4):277–88. https://doi.org/10.1080/10550490902925540.
Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530–3. https://doi.org/10.1136/bmj.320.7248.1530.
Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res. 2002;37(6):1681–705. https://doi.org/10.1111/1475-6773.01115.
Viney R, Lancsar E, Louviere J. Discrete choice experiments to measure consumer preferences for health and healthcare. Expert Rev Pharmacoecon Outcomes Res. 2002;2(4):319–26. https://doi.org/10.1586/14737126.96.36.1999.
Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics. 2008;26(8):661–77. https://doi.org/10.2165/00019053-200826080-00004.
Opuni M, Bishai D, Gray GE, Mcintyre JA, Martinson NA. Preferences for characteristics of antiretroviral therapy provision in Johannesburg, South Africa: results of a conjoint analysis. AIDS Behav. 2010;14(4):807–15. https://doi.org/10.1007/s10461-009-9584-4.
Anderson CW, Smith HR. Stigma and honor: gay, lesbian, and bisexual people in the US military. In: Diamant L, editor. Homosexual issues in the workplace. Washington, DC: Taylor and Francis; 1993. p. 65–89.
Biddix JM, Fogel CI, Perry BB. Comfort levels of active duty gay/bisexual male service members in the military healthcare system. Mil Med. 2013;178(12):1335–40. https://doi.org/10.7205/MILMED-D-13-00044.
Russell TG. An examination of stigma in the military; 2013.
Lloyd J, Papworth E, Grant L, Beyrer C, Baral S. Systematic review and meta-analysis of HIV prevalence among men in militaries in low income and middle income countries. Sex Transm Infect. 2014;90(5):382–7. https://doi.org/10.1136/sextrans-2013-051463.
Hakre S, Blaylock JM, Dawson P, Beckett C, Garges EC, Michael NL, et al. Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US air force health care providers. Medicine (Baltimore). 2016;95(32):e4511. https://doi.org/10.1097/MD.0000000000004511.
Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256–62. https://doi.org/10.1258/ijsa.2009.009255.
Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238. https://doi.org/10.1371/journal.pone.0028238.
Wheelock A, Eisingerich AB, Ananworanich J, Gomez GB, Hallett TB, Dybul MR, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One. 2013;8(1):e54288. https://doi.org/10.1371/journal.pone.0054288.
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, et al. Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. 2018;22(4):1228–38. https://doi.org/10.1007/s10461-017-1851-1.
Shrestha R, Altice F, Karki P, Copenhaver M. Developing an integrated, brief biobehavioral HIV prevention intervention for high-risk drug users in treatment: the process and outcome of formative research. Front Immunol. 2017;8:561. https://doi.org/10.3389/fimmu.2017.00561.
Toubia O, Hauser J, Garcia R. Probabilistic polyhedral methods for adaptive choice-based conjoint analysis: theory and application. Marketing Sci. 2007;26(5):596–610. https://doi.org/10.1287/mksc.1060.0257.
Chapman C, Alford J, Johnson C, Weidemann R, Lahav M. CBC vs. ACBC: comparing results with real product selection. Sawtooth Software Conference Proceedings, Sequim, WA; 2009.
Cunningham CE, Deal K, Chen Y. Adaptive choice-based conjoint analysis: a new patient-centered approach to the assessment of health service preferences. Patient. 2010;3(4):257–73. https://doi.org/10.2165/11537870-000000000-00000.
Lowe B, Kroenke K, Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res. 2005;58(2):163–71. https://doi.org/10.1016/j.jpsychores.2004.09.006.
Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med. 1997;12(7):439–45. https://doi.org/10.1046/j.1525-1497.1997.00076.x.
Wilton J, Kain T, Fowler S, Hart TA, Grennan T, Maxwell J, et al. Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. J Int AIDS Soc. 2016;19(1):20777. https://doi.org/10.7448/IAS.19.1.20777.
Software S. Lighthouse studio v9.0 (formerly SSIWeb). Sawtooth Software: Orem, UT; 2016.
Software S. Hosting security information. 2018. https://www.sawtoothsoftware.com/88-services/hosting/1457-hosting-security-information.
Orme B. Consistency cutoffs to identify "bad" respondents in CBC, ACBC, and MaxDiff. Sawtooth Software Research Paper Series; 2019.
Lenk P, Desarbo W, Green P, Young M. Hierarchical bayes conjoint analysis: recovery of partworth heterogeneity from reduced experimental designs. Marketing Sci. 1996;15(2):173–91. https://doi.org/10.1287/mksc.15.2.173.
Rao V. Applied conjoint analysis. Germany: Springer-Verlag Berlin Heidelberg; 2013.
Herrmann A, Gustafsson A, Huber F. Conjoint measurement: methods and applications. Germany: Springer-Verlag Berlin Heidelberg; 2007.
Orme B. Getting started with conjoint analysis: Strategies for product design and pricing research. 2nd ed. Madison: Research Publishers LLC; 2010.
Millar BM, Starks TJ, Grov C, Parsons JT. Sexual risk-taking in HIV-negative gay and bisexual men increases with depression: results from a U.S. National Study. AIDS Behav. 2017;21(6):1665–75. https://doi.org/10.1007/s10461-016-1507-6.
Fendrich M, Avci O, Johnson TP, Mackesy-Amiti ME. Depression, substance use and HIV risk in a probability sample of men who have sex with men. Addict Behav. 2013;38(3):1715–8. https://doi.org/10.1016/j.addbeh.2012.09.005.
Parsons JT, Grov C, Golub SA. Sexual compulsivity, co-occurring psychosocial health problems, and HIV risk among gay and bisexual men: further evidence of a syndemic. Am J Public Health. 2012;102(1):156–62. https://doi.org/10.2105/AJPH.2011.300284.
HPTN 083, Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men | The HIV Prevention Trials Network. . https://www.hptn.org/news-and-events/press-releases/long-acting-injectable-cabotegravir-highly-effective-prevention-hiv. Accessed 3 May 2021.
World Health Organization. Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women. Accessed November 9, 2020. https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women.
2019 IAS. First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year. International AIDS Society. Available from http://programme.ias2019.org/Abstract/Abstract/4843. 2019.
Greene GJ, Swann G, Fought AJ, Carballo-Dieguez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2017;21(5):1336–49. https://doi.org/10.1007/s10461-016-1565-9.
Gleason JL, Beck KH. Examining associations between relocation, continuity of care, and patient satisfaction in military spouses. Mil Med. 2017;182(5–6):e1657–64. https://doi.org/10.7205/MILMED-D-16-00191.
Brown RA, Marshall GN, Breslau J, Farris C, Osilla KC, Pincus HA, et al. Access to behavioral health care for geographically remote service members and dependents in the U.S. Rand Health Q. 2015;5(1):21.
Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, et al. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10. https://doi.org/10.1007/s10461-015-0996-z.
Hernandez-Romieu AC, Sullivan PS, Sanchez TH, Kelley CF, Peterson JL, Del Rio C, et al. The comparability of men who have sex with men recruited from venue-time-space sampling and facebook: a cohort study. JMIR Res Protoc. 2014;3(3):e37. https://doi.org/10.2196/resprot.3342.
Grov C, Westmoreland D, Rendina HJ, Nash D. Seeing is believing? Unique capabilities of internet-only studies as a tool for implementation research on HIV prevention for men who have sex with men: A review of studies and methodological considerations. J Acquir Immune Defic Syndr. 2019;82 Suppl 3(Suppl 3):S253–60.
This study was supported by F31 grant number F31NR018620-01A1 by the National Institute of Nursing Research (NINR), the National Institute of Mental Health (NIMH), Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) under award number P30MH059107. Carmen Portillo and Nancy R. Reynolds provided review on earlier versions of this manuscript.
Research reported in this publication was supported by the National Institute of Nursing Research (NINR), under award number 1F31NR018620-01A1. This work was also supported by the National Institute of Mental Health (NIMH), Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) under award number P30MH059107. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.
Ethics approval and consent to participate
The study was approved by the Yale University Institutional Review Board (IRB Protocol ID: 2000024612). Social media group administrators placed monthly advertisement links describing the study on the group’s main forum. Interested participants could click on a link to access an online study disclosure form with a ‘click to consent’ procedure.
Consent for publication
The authors declare that they have no competing interests.
About this article
Cite this article
Gutierrez, J.I., Dubov, A., Altice, F.L. et al. Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. Military Med Res 8, 32 (2021). https://doi.org/10.1186/s40779-021-00323-6